Which IBD Medication Is Right for You? 5 Key Factors to Consider
Health ConditionsDigestive Health

Which IBD Medication Is Right for You? 5 Key Factors to Consider

Age, disease severity, and previous treatments all play a role in choosing the best Crohn’s or ulcerative colitis medication for you.
Which IBD Medication Is Right for You? 5 Key Factors to Consider
Marc Tran/Stocksy; iStock
By
Published on May 22, 2025
by
Inflammatory bowel disease (IBD) is a complex, lifelong condition that includes Crohn’s disease and ulcerative colitis. One of the most common questions patients ask me is, “Which medication is right for me?” The answer is rarely simple. There’s no one-size-fits-all approach because each person’s treatment plan depends on several unique factors.

The great news is that today, there are more effective and diverse treatment options for IBD than ever before, thanks to recent advances in medications and therapies. With so many choices available, it’s understandable that the process can feel overwhelming.

Alan Moss
There’s no one-size-fits-all approach because each person’s treatment plan depends on several unique factors.
— Alan Moss, MD, chief scientific officer at the Crohn’s & Colitis Foundation
The best medication for you will depend on your specific diagnosis, the severity and activity of your disease, your previous experiences with treatments, your age and life stage, and your personal preferences. By understanding what factors matter most, you can work with your healthcare team to find a plan that fits your needs and lifestyle.

To help patients and caregivers make informed decisions, the Crohn’s & Colitis Foundation offers an easy-to-use IBD Medication Guide, which provides up-to-date information on all treatments that are approved by the U.S. Food and Drug Administration (FDA).

Here are five important considerations to discuss with your doctor when choosing an IBD medication.

1. Disease Location: Crohn’s Disease vs. Ulcerative Colitis

Your specific diagnosis — Crohn’s disease or ulcerative colitis — guides many treatment decisions. These two forms of IBD affect different parts of the digestive tract and may respond differently to certain medications.

For example, a group of IBD medications called aminosalicylates (5-ASA drugs) are effective for mild to moderate ulcerative colitis but are less helpful for Crohn’s disease, especially when the small intestine is involved. Different types of medications called immunomodulators, biologics, and small molecule therapies are FDA-approved for Crohn’s disease, ulcerative colitis, or both.

The location of your disease influences which treatment is right for you; for example, vedolizumab (Entyvio) targets only the intestinal tract, whereas ustekinumab (Stelara) targets both the intestinal tract and other inflamed organs, such as skin or joints.

2. Disease Activity

How severe your IBD is at the time you’re evaluated is a key factor in treatment choice. Disease activity refers to your current symptoms and test results, such as blood work, stool markers like fecal calprotectin (a protein released by inflammatory cells in the digestive tract), and endoscopy findings. Active disease can be mild, moderate, or severe; more severe disease increases the risk of complications or the need for hospitalization.

For mild disease, your doctor may recommend medications like 5-ASAs or steroids (temporarily) and select formulations that act primarily in the colon. For moderate to severe disease, more systemic therapies, such as immunomodulators, biologics, or small molecule inhibitors, are often needed to dampen the inflammation. If you have a severe flare, treatment may need to start quickly, sometimes with intravenous medications or steroids to control inflammation and prevent complications.

Your doctor will consider how often you’ve had flare-ups and hospital stays or needed steroids in the past to help choose the best medication for you.

3. Previous Medication Exposure and Treatment Response

Your past experiences with IBD medications — what you’ve tried, what worked, and what didn’t — are critical in shaping your current treatment plan. If you have previously used certain advanced therapies (like antitumor necrosis factor [TNF] biologics) and they stopped working for you or caused side effects, your doctor may recommend switching to a medication with a different way of working, such as an interleukin (IL)-12/23 inhibitor or a Janus kinase (JAK) inhibitor.

The first biologic you use often has the highest chance of long-term effectiveness, so making an informed choice early on is valuable.

If you are stable and in remission, there is usually no need to switch medications unless you develop side effects or it stops working for you. Stopping an effective medication is generally discouraged; about half of patients who discontinue therapy will experience a return of their symptoms.

4. Special Scenarios: Age, Pregnancy, and Extraintestinal Symptoms

Certain life stages and health situations can affect which medications are safest and most effective.

For children and teens, not all medications are approved or available. Growth and bone health are especially important to consider because IBD can interfere with them. If not addressed, these issues can result in reduced final height as an adult and long-term bone health problems.

 Pediatric IBD often involves more extensive disease and may require early use of advanced therapies to support growth and development.
For older adults, the safety of each medication is carefully considered. Some biologics, such as anti-integrin or IL-12/23 inhibitors, are often favored for their lower risk of systemic (whole-body) side effects. If you are pregnant or planning pregnancy, most biologics are considered safe and are continued during pregnancy, but JAK inhibitors should be avoided.

Some people with IBD also experience symptoms outside the gut, such as joint pain or skin rashes.

 In these cases, medications that target inflammation both inside and outside the intestines — like anti-TNF drugs or certain small molecule inhibitors — may be preferred.

5. Lifestyle, Preferences, and Shared Decision-Making

Your personal preferences and lifestyle should play a major role in choosing the right IBD medication. Considerations include:

  • How the medication is taken (oral pill, self-injection, or intravenous [IV] infusion in a clinic)
  • How often you need to take or receive the medication (daily, weekly, or every eight weeks)
  • Your comfort with needles or infusions
  • The impact of the medication on your daily life, work, or school schedule
  • Insurance coverage and cost (sometimes your plan will dictate which medications are and are not covered)
Shared decision-making is essential. You and your healthcare team should work together to weigh the benefits and risks of each option, taking into account your goals, values, and concerns. Open communication and regular follow-up are key to finding the best treatment for you and adjusting it as your needs change.

By working closely with your healthcare team and staying informed, you can find a treatment plan that helps you achieve remission and maintain a good quality of life.

The Takeaway

  • If you have Crohn’s or ulcerative colitis, there’s no one-size-fits-all approach for choosing the right medication for you.
  • You and your gastroenterologist should consider factors like disease location, disease activity, previous medication use, lifestyle, preferences, and specific lifestyle factors, such as age or pregnancy.
  • Communicating openly with your doctor and attending regular follow-up appointments are key to ensuring you’re on the best possible treatment plan.

Resources We Trust

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Medication. Crohn’s & Colitis Foundation.
  2. Inflammatory Bowel Disease. Cleveland Clinic.
  3. Understanding IBD Medications and Side Effects. Crohn’s & Colitis Foundation. March 2021.
  4. Medication for Inflammatory Bowel Disease. NYU Langone Health.
  5. Crohn’s Disease. Mayo Clinic. October 29, 2024.
  6. Berg DR et al. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflammatory Bowel Diseases. December 2019.
  7. Torres J et al. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology. December 2015.
  8. Wong K et al. Growth Delay in Inflammatory Bowel Diseases: Significance, Causes, and Management. Digestive Diseases and Sciences. April 2021.
  9. Complications and Extraintestinal Manifestations. Crohn’s & Colitis Canada.
  10. Song K et al. Shared Decision-Making in the Management of Patients With Inflammatory Bowel Disease. World Journal of Gastroenterology. July 14, 2022.
Meet Our Experts
See Our Editorial PolicyMeet Our Health Expert Network

Yuying Luo, MD

Medical Reviewer

Yuying Luo, MD, is an assistant professor of medicine at Mount Sinai West and Morningside in New York City. She aims to deliver evidence-based, patient-centered, and holistic care for her patients.

Her clinical and research focus includes patients with disorders of gut-brain interaction such as irritable bowel syndrome and functional dyspepsia; patients with lower gastrointestinal motility (constipation) disorders and defecatory and anorectal disorders (such as dyssynergic defecation); and women’s gastrointestinal health.

She graduated from Harvard with a bachelor's degree in molecular and cellular biology and received her MD from the NYU Grossman School of Medicine. She completed her residency in internal medicine at the Icahn School of Medicine at Mount Sinai, where she was also chief resident. She completed her gastroenterology fellowship at Mount Sinai Hospital and was also chief fellow.

See full bio
Alan Moss

Alan Moss, MD

Author
From Crohn's & Colitis Foundation

Alan Moss, MD, is a renowned clinician-scientist who serves as the chief scientific officer at the Crohn’s & Colitis Foundation. His prior roles include serving as the director of the Crohn’s & Colitis Program at Boston Medical Center (BMC) and professor of medicine at Boston University (BU). In his clinical practice, Dr. Moss has cared for IBD patients from underserved, immigrant, and unhoused populations.

His research spans microbial therapeutics, mucosal immunology, and clinical outcomes. Moss has published more than 200 peer-reviewed articles.

Prior to joining BMC and BU, Moss was an associate professor of medicine at Harvard Medical School and an IBD physician at Beth Israel Deaconess Medical Center (BIDMC), where he was also the director of translational research. He also served as an associate investigator at both Mass General Hospital and Massachusetts Institute of Technology.

Moss has held positions as deputy-editor of Crohn’s & Colitis 360, and as associate editor for Journal of Crohn’s & Colitis (ECCO), Frontline Gastroenterology (BMJ) and the World Journal of Gastroenterology. He has served on the nominating committee of the IBD section of American Gastroenterological Association, and the Professional Education and National Scientific Advisory Committee for the Crohn’s & Colitis Foundation. He is a reviewer for national and international research bodies, including the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and European Research Council.

Moss received his medical education and training in Ireland at RCSI Medical School in Dublin and continued his medical training in the United  States through a fellowship at BIDMC.

See full bio
See Our Editorial PolicyMeet Our Health Expert Network